Time and predictors of response to tumour necrosis factor-α blockers in psoriatic arthritis: An analysis of a longitudinal observational cohort

Rheumatology

Volumn 49, Issue 7, 2010, Pages 1361-1366

  Eder, Lihi ^a   Chandran, Vinod ^a   Schentag, Catherine T ^a   Shen, Hua ^b   Cook, Richard J ^b   Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Blockers; Delayed response; Effectiveness; Psoriatic arthritis; TNF

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT FUNCTION; JOINT SWELLING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SCORING SYSTEM; TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954200112     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq091     Document Type: Article

References (16)

1. Bruce IN. Psoriatic arthritis: clinical features. In: Hochberg M, Silman A, Smolen J, Weinblatt ME, Weisman M, eds. Rheumatology. 3rd edition. Philadelphia: Mosby, 2003:1241-52.
2. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005; 64(Suppl. 2):ii78-82.
3. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90.
4. Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7.
5. National Institute for Health and Clinical Excellence. Final appraisal determination: etanercept and infliximab for the treatment of adults with psoriatic arthritis. http://guidance.nice.org.uk/TA104#summary 2006 (15 March 2010, date last accessed).
6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
7. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis - clinical and laboratory analysis of 220 patients. Q J Med 1987;62:127-41.
8. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl. 2):ii49-54.
9. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
10. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
11. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52: 3279-89.
12. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
13. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444-7.
14. Gratacós J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007; 66:493-7.
15. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67:364-9.
16. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.